Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 12.5 vs COLESTIPOL HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
Attention deficit hyperactivity disorder (ADHD),Narcolepsy (off-label)
Primary hypercholesterolemia (FDA-approved adjunct to diet),Pruritus associated with partial biliary obstruction,Pseudomembranous enterocolitis (off-label, as colestipol binds Clostridium difficile toxins),Digitoxin toxicity (off-label, to interrupt enterohepatic circulation),Bile acid malabsorption (off-label)
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life.
Amphetamine and dextroamphetamine are extensively metabolized in the liver via CYP2D6 and other pathways. The primary metabolites are 4-hydroxyamphetamine and 4-hydroxynorephedrine.
Not metabolized; not absorbed systemically.
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is p H-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs.
Approximately 15–20% bound to plasma proteins, primarily albumin.
Not applicable; the drug is not absorbed and does not bind to plasma proteins.
Mean volume of distribution is 3.5–4.6 L/kg, indicating extensive tissue distribution. Clinical meaning: Large Vd reflects sequestration in tissues (including brain), contributing to prolonged presence.
Not applicable; colestipol is not absorbed and remains within the gastrointestinal lumen.
Oral bioavailability is highly variable, ranging from 75–100% for immediate-release tablets; food does not significantly affect overall absorption but may delay time to peak concentration. Extended-release capsules have bioavailability approximately 96% relative to immediate-release.
0% for systemic absorption; it is non-absorbable and acts locally in the intestine.
GFR 15-29 m L/min: reduce dose to 50% of usual; GFR <15 m L/min: use 50% of usual dose; hemodialysis: not removed, avoid use.
No specific dose adjustment recommended; use with caution in severe renal impairment due to potential for hyperchloremic metabolic acidosis.
Child-Pugh A: no adjustment; Child-Pugh B: use 50% of usual dose; Child-Pugh C: avoid use.
No specific dose adjustment recommended; caution in severe hepatic impairment due to possible decreased cholesterol synthesis.
Immediate-release: 3-5 years: initial 2.5 mg once daily, increase by 2.5 mg weekly up to 40 mg/day; 6+ years: initial 5 mg once or twice daily, increase by 5 mg weekly up to 40 mg/day. Extended-release: 6-12 years: initial 10 mg once daily, increase by 10 mg weekly up to 30 mg/day; 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day.
Not established for children <10 years; for ≥10 years, initial: 5 g orally once daily; increase gradually to 5-20 g/day divided once or twice daily.
Start at lowest dose (5 mg immediate-release or 10 mg extended-release) and titrate slowly due to increased risk of adverse cardiovascular and CNS effects; monitor for hypertension, tachycardia, and agitation.
No specific dose adjustment; monitor for gastrointestinal adverse effects and potential interactions with other medications due to altered GI motility and polypharmacy.
Adderall has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
No FDA black box warning.
Risk of abuse and dependence,Serious cardiovascular events including sudden death, stroke, and myocardial infarction,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with seizure disorders,Visual disturbances,Growth suppression in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when used with serotonergic drugs
May cause hypertriglyceridemia,Risk of vitamin K deficiency and bleeding (due to bile acid binding),May impair absorption of fat-soluble vitamins (A, D, E, K),May cause constipation or fecal impaction (especially in elderly),May interfere with absorption of other drugs (e.g., warfarin, thyroid hormones, digoxin); separate administration by at least 1 hour or as specified
Known hypersensitivity to amphetamine products or other sympathomimetic amines,Concomitant use with MAOIs or within 14 days of MAOI therapy,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease including moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, or tachyarrhythmias
Hypersensitivity to colestipol hydrochloride or any component,Complete biliary obstruction,Phenylketonuria (if formulation contains aspartame)
Avoid acidic foods and beverages (e.g., citrus fruits, soda) within 1 hour of administration as they may decrease absorption. High-fat meals may delay absorption of extended-release formulations. Avoid caffeine and other stimulants. Grapefruit juice may increase amphetamine levels.
Colestipol can bind to dietary fats and fat-soluble vitamins (A, D, E, K). Take supplements at least 1 hour before or 4-6 hours after colestipol. High-fiber foods may reduce binding but are generally encouraged to prevent constipation. Avoid grapefruit juice? No significant interaction.
First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and third trimesters: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress). Premature delivery and growth restriction have been reported.
Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known adverse fetal effects.
Contraindicated due to potential for infant toxicity. M/P ratio not established; amphetamine is excreted into breast milk in small amounts but may accumulate in breastfeeding infants. Adverse effects include irritability, poor feeding, and decreased weight gain.
Colestipol is not absorbed systemically and not excreted into breast milk. Compatible with breastfeeding. M/P ratio not applicable.
Pharmacokinetics altered: increased hepatic metabolism and renal clearance in pregnancy may reduce amphetamine exposure; however, safety data do not support dose adjustment. Use lowest effective dose only if necessary; consider alternative non-amphetamine therapies.
No dose adjustment required due to lack of systemic absorption. Monitor for potential fat-soluble vitamin deficiency and supplement if needed.
ADDERALL 12.5 mg is a fixed-dose combination of amphetamine and dextroamphetamine. Monitor for cardiovascular events, especially in patients with pre-existing heart conditions. Onset of action occurs within 30-60 minutes; duration of action is approximately 4-6 hours. Avoid late afternoon doses to prevent insomnia. Use with caution in patients with a history of drug abuse. May cause growth suppression in children; monitor height and weight. Do not crush or chew extended-release capsules.
Colestipol hydrochloride is a bile acid sequestrant used as adjunctive therapy for primary hyperlipidemia. It may increase triglyceride levels; monitor triglycerides before initiation. Administer other medications 1 hour before or 4-6 hours after colestipol to reduce absorption interference. Use with caution in constipation-prone patients; encourage high-fiber diet and adequate fluid intake. Can bind thyroxine, warfarin, digoxin, and fat-soluble vitamins.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Swallow the capsule whole; do not chew, crush, or open it.,Avoid alcohol while taking this medication.,Do not drive or operate machinery until you know how this medication affects you.,Report any chest pain, shortness of breath, or fainting to your doctor immediately.,Store at room temperature away from moisture and heat.
Take colestipol with meals and plenty of water (at least 8 oz).,Do not take other medications within 1 hour before or 4-6 hours after colestipol.,May cause constipation; increase dietary fiber and fluid intake.,Report severe constipation, abdominal pain, or unusual bleeding.,Continue prescribed diet and exercise regimen.,Store at room temperature; do not freeze.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 12.5 vs COLESTIPOL HYDROCHLORIDE, answered by our medical review team.
ADDERALL 12.5 is a CNS Stimulant that works by Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.. COLESTIPOL HYDROCHLORIDE is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 12.5 and COLESTIPOL HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 12.5 is: 5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.. The standard adult dose of COLESTIPOL HYDROCHLORIDE is: Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 12.5 and COLESTIPOL HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 12.5 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and th. COLESTIPOL HYDROCHLORIDE is classified as Category C. Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.